About this trial
Despite declining incidence rates, gastric cancer (GC) ranks the fourth leading cause of cancer-related mortality and the fifth most common cancer worldwide, with the highest incidence reported in Eastern Asia. The 5-year overall survival rate of early GC exceeds 90%, which was well above advanced GC. Most intestinal-type GCs follow the Correa cascade-inflammation,atrophy, intestinal metaplasia (IM), dysplasia and subsequent carcinoma. The presence of gastric mucosal atrophy and intestinal metaplasia are important risk factors for GC. The purpose of this study was to investigate the incidence of GC attributed to atrophic gastritis in a region with high incidence of GC.
Eligibility criteria
Qualifiers
Ability and willingness to participate in the study and to sign and give informed consent
Biopsies were collected based on the recommendation of updated Sydney system
Disqualifiers
under 18 or over 80 years old
history of gastrectomy
severe systemic diseases or malignancy
Trial design
Treatments tested in this trial
- Esophagogastroscopy (OLGA 0-Ⅰ)
- Esophagogastroscopy (OLGA II)
- Esophagogastroscopy (OLGA III-IV)
Treatment groups
Sponsors and collaborators
Shanghai Jiao Tong University School of Medicine
Lead sponsor
RenJi Hospital
Sponsor institution